Synthetic biology startup StrainX Bioworks has raised $13 million in a funding round co-led by Prime Venture Partners and Leo Capital. The round also saw participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dhoka Ventures, and WTF (India) Delhi Angels.
The newly raised capital will be used to strengthen the company’s research and development capabilities, expand its fermentation infrastructure, grow its scientific and engineering workforce, and accelerate commercialisation efforts across domestic and international markets.
The funding marks a significant milestone for the young biotechnology company as it moves closer to large-scale commercial deployment of its precision fermentation platform.
Building Alternative Proteins Through Biotechnology
Founded in 2023 by Akshay Mittal and Alok Malaviya, StrainX Bioworks operates in the synthetic biology and precision fermentation space. The startup focuses on developing alternative proteins and other high-value biological ingredients for industries including food, healthcare, and agriculture.
The company develops proprietary enzymes, proteins, and metabolites using advanced biological engineering techniques. These products are designed to serve a growing demand for sustainable and scalable alternatives to conventionally sourced ingredients.
By combining biotechnology with industrial-scale manufacturing processes, StrainX aims to create solutions that can support future food and nutrition needs while reducing dependence on traditional production systems.
Also Read: From Kathi Rolls to ₹100 Crore: Inside RollsKing’s Fast-Casual Growth Story
Two Years of Foundation Building in Stealth Mode
According to the company, the past two years have been dedicated to building a strong technological and operational foundation while operating in stealth mode.
During this period, StrainX invested heavily in key capabilities such as strain engineering, fermentation technology, process scale-up, and product development. These areas form the backbone of precision fermentation, a technology that enables microorganisms to produce valuable proteins and ingredients in controlled environments.
The startup’s approach is centered on engineering biological systems capable of producing high-value food ingredients and alternative proteins efficiently. The company believes this model can contribute to a more sustainable and resilient food supply chain in the years ahead.
Scaling Production for Commercial Markets
As it prepares for broader commercial operations, StrainX has already achieved an important production milestone. The company stated that it has successfully demonstrated fermentation at a 10,000-litre scale, a step that highlights its progress toward industrial-scale manufacturing.
With the fresh funding in place, the startup plans to further increase production capacity and accelerate its path to commercialisation. The company is targeting opportunities both in India and in international markets, including the United States.
The ability to scale production efficiently is considered a critical factor in the precision fermentation industry, where companies must bridge the gap between laboratory innovation and cost-effective commercial manufacturing.
An Integrated Platform for Faster Innovation
StrainX’s platform combines multiple components of the biotechnology value chain into a unified system. These include strain engineering, fermentation infrastructure, process engineering, and product development.
By integrating these capabilities under one platform, the company aims to shorten development timelines and improve the transition from scientific discovery to industrial production. This approach is intended to help bring new biological products to market more efficiently while maintaining scalability.
The company sees this integrated model as a key differentiator as demand for sustainable ingredients and alternative proteins continues to grow globally.
The Growing Role of Synthetic Biology
Synthetic biology involves designing and engineering microorganisms to produce molecules that have traditionally been sourced from plants or animals. Once engineered, these microbes are grown through industrial fermentation processes that can manufacture proteins and other ingredients in controlled settings.
The technology has long been used in pharmaceutical production, but its applications are expanding into sectors such as food, nutrition, agriculture, and consumer products. As advances in biotechnology continue and production costs decline, more companies are exploring precision fermentation as a viable method for producing sustainable ingredients at scale.
With its latest funding round, StrainX Bioworks is positioning itself to play a larger role in this evolving sector, focusing on the development and commercial production of next-generation biological ingredients and alternative proteins for global markets.
Also Read: Scapia’s $63 Million Raise Signals a Bigger Bet on India’s Travel Payments Market
